Scienture Holdings, Inc. (Nasdaq: SCNX) has entered into a securities purchase agreement with institutional investors for a registered direct offering of 3,225,000 shares of common stock at an offering price of $1.20 per share, expecting gross proceeds of approximately $3.9 million.
The offering is set to close on August 15, 2025, subject to customary closing conditions.
Maxim Group LLC is the sole placement agent for the offering.
Offering Details
3,225,000 shares of common stock at $1.20 per share, expected gross proceeds of around $3.9 million.
Closing Date
The offering is expected to close on August 15, 2025.
Placement Agent
Maxim Group LLC is acting as the sole placement agent in connection with the offering.
- The registered direct offering signifies Scienture Holdings' strategic move to secure additional funding for its operations and growth plans.
- The successful completion of the offering is crucial for the Company to execute its business strategies and bring novel specialty products to the market.
- This move showcases investor confidence in Scienture Holdings and its potential for providing enhanced value to patients, physicians, and caregivers.
The announcement of the registered direct offering reflects Scienture Holdings' commitment to advancing its pharmaceutical product offerings and delivering value to stakeholders in the healthcare industry.